Ranbaxy gets $440m CB, shows mispricing is alive and well

17 Feb 2006

Indian pharmaceutical company Ranbaxy Laboratories issued a $440m convertible bond on Wednesday evening Indian time that had to be re-offered at 99.00 but still struggled in the secondary market.

Citigroup, Deutsche Bank, Morgan Stanley and UBS led the deal. The bond was quoted below 99.00 yesterday (Thursday) afternoon after ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

Oops, something went wrong

We're sorry but at the moment we can't load this data